Evelo Biosciences, Inc.
EVLO · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $2 | $0 | $0 |
| Gross Profit | -$1 | -$2 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6 | $13 | $18 | $16 |
| G&A Expenses | $4 | $5 | $7 | $5 |
| SG&A Expenses | $4 | $5 | $7 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $10 | $18 | $25 | $21 |
| Operating Income | -$11 | -$20 | -$25 | -$21 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1 | -$1 | -$0 | -$2 |
| Pre-Tax Income | -$12 | -$21 | -$25 | -$23 |
| Tax Expense | -$0 | $0 | $0 | $1 |
| Net Income | -$12 | -$21 | -$25 | -$24 |
| % Margin | – | – | – | – |
| EPS | -71.12 | -3.78 | -4.57 | -4.29 |
| % Growth | -1,781.5% | 17.3% | -6.5% | – |
| EPS Diluted | -71.12 | -3.78 | -4.57 | -4.29 |
| Weighted Avg Shares Out | 0 | 6 | 6 | 5 |
| Weighted Avg Shares Out Dil | 0 | 6 | 6 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $2 |
| Depreciation & Amortization | $0 | $0 | $0 | $1 |
| EBITDA | -$11 | -$19 | -$24 | -$21 |
| % Margin | – | – | – | – |